Here are the 8-K filings from Seaport Therapeutics, Inc. (SPTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow SPTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SPTX filings page.
Seaport Therapeutics, Inc. reported third-quarter 2026 net loss of $26.394 million, compared with $22.544 million a year earlier. Research and development expenses were $23.891 million versus $20.453 million, and general and administrative expenses were $6.454 million versus $4.988 million. Cash, cash equivalents and investments totaled $403.799 million as of September 30, 2026; the company expects these resources to support current operating plans into 2029 and through three mid-to-late-stage data readouts.
A Phase 1 driving simulation trial found that evening GlyphAllo doses of 375 mg after multiple-day dosing on Day 5 and a single 250 mg dose on Day 2 did not impair next-morning driving performance compared with placebo; no serious adverse events were reported. BUOY-1, a Phase 2b GlyphAllo trial in major depressive disorder, is enrolling, with topline data expected in the first half of 2027. Seaport dosed the first patient in its GlyphAgo Phase 2a trial for generalized anxiety disorder and sleep disturbance, and expects to initiate a Phase 2/3 GAD trial in the first half of 2027. Topline data are expected in early 2028 from Phase 2a and by year-end 2028 from Phase 2/3.
Seaport Therapeutics reported second-quarter 2026 results and detailed progress across its neuropsychiatry pipeline. Enrollment in the Phase 2b BUOY-1 trial of GlyphAllo in major depressive disorder is on track, with topline data expected in the first half of 2027, and a Phase 1 driving-simulation trial is expected to read out in the second half of 2026.
The company reported positive Phase 1 proof-of-concept data for GlyphAgo in generalized anxiety disorder, including a 6.8-fold increase in bioavailability and 10-fold lower pharmacokinetic variability versus unmodified agomelatine, supporting planned Phase 2a and 2b trials starting in 2026 and 2027. Preclinical candidate Glyph2BLSD is expected to complete first-in-human-enabling studies by year-end 2027.
In May 2026 Seaport completed an upsized IPO raising $260.0 million in gross proceeds, ending June 30, 2026 with $427.3 million in cash, cash equivalents, and investments, which it expects to fund operations into 2029. Higher R&D and one-time, non-cash stock-based compensation drove a wider net loss of $62.6 million for the quarter, compared with $15.1 million a year earlier.
Seaport Therapeutics reported a larger first-quarter 2026 loss while significantly strengthening its balance sheet and advancing its neuropsychiatry pipeline. Net loss was $25.4M, compared with $13.1M a year earlier, driven mainly by higher research and development spending of $21.4M as lead programs moved into later-stage trials.
Cash, cash equivalents, and investments totaled $212.6M as of March 31, 2026. In May, Seaport completed an upsized IPO generating gross proceeds of $260.0M, and now expects its current cash to fund operations into 2029. The company highlighted progress across its GlyphAllo and GlyphAgo programs, including a potentially registration-enabling Phase 2b MDD trial, new Phase 1 data supporting dose selection in GAD, and plans for multiple Phase 2 studies with topline readouts extending through 2028.